Les traitements antérieurs affectent-ils les risques ?
Oui, des traitements antérieurs peuvent influencer la réponse aux thérapies CRISPR.
Traitements antérieursRéponseProtéines CRISPR
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines associées aux CRISPR : Questions médicales les plus fréquentes",
"headline": "Protéines associées aux CRISPR : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines associées aux CRISPR : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-15",
"dateModified": "2025-02-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines associées aux CRISPR"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines",
"url": "https://questionsmedicales.fr/mesh/D011506",
"about": {
"@type": "MedicalCondition",
"name": "Protéines",
"code": {
"@type": "MedicalCode",
"code": "D011506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine-9 associée à CRISPR",
"alternateName": "CRISPR-Associated Protein 9",
"url": "https://questionsmedicales.fr/mesh/D000076987",
"about": {
"@type": "MedicalCondition",
"name": "Protéine-9 associée à CRISPR",
"code": {
"@type": "MedicalCode",
"code": "D000076987",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.212.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protéines associées aux CRISPR",
"alternateName": "CRISPR-Associated Proteins",
"code": {
"@type": "MedicalCode",
"code": "D064130",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yi Zhang",
"url": "https://questionsmedicales.fr/author/Yi%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China."
}
},
{
"@type": "Person",
"name": "Yue Feng",
"url": "https://questionsmedicales.fr/author/Yue%20Feng",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Electronic address: fengyue@mail.buct.edu.cn."
}
},
{
"@type": "Person",
"name": "Joseph Bondy-Denomy",
"url": "https://questionsmedicales.fr/author/Joseph%20Bondy-Denomy",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94143, USA."
}
},
{
"@type": "Person",
"name": "Alan R Davidson",
"url": "https://questionsmedicales.fr/author/Alan%20R%20Davidson",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: alan.davidson@utoronto.ca."
}
},
{
"@type": "Person",
"name": "Xu Peng",
"url": "https://questionsmedicales.fr/author/Xu%20Peng",
"affiliation": {
"@type": "Organization",
"name": "Department of Biology, University of Copenhagen, Copenhagen N, Denmark. Electronic address: peng@bio.ku.dk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Effective data quality management for electronic medical record data using SMART DATA.",
"datePublished": "2023-10-12",
"url": "https://questionsmedicales.fr/article/37871445",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijmedinf.2023.105262"
}
},
{
"@type": "ScholarlyArticle",
"name": "Over-interpretation of findings in diagnostic accuracy studies of infectious diseases.",
"datePublished": "2023-03-15",
"url": "https://questionsmedicales.fr/article/36925106",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cmi.2023.03.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "The IeDEA harmonist data toolkit: A data quality and data sharing solution for a global HIV research consortium.",
"datePublished": "2022-06-06",
"url": "https://questionsmedicales.fr/article/35680074",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jbi.2022.104110"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Not all published data are reliable: fabricated data in medical research].",
"datePublished": "2024-05-22",
"url": "https://questionsmedicales.fr/article/38780192",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "Influence on the accuracy in ChatGPT: Differences in the amount of information per medical field.",
"datePublished": "2023-11-03",
"url": "https://questionsmedicales.fr/article/37931432",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijmedinf.2023.105283"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines associées aux CRISPR",
"item": "https://questionsmedicales.fr/mesh/D064130"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines associées aux CRISPR - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines associées aux CRISPR",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines associées aux CRISPR",
"description": "Comment identifier les protéines CRISPR dans un échantillon ?\nQuels tests sont utilisés pour détecter les protéines associées ?\nPeut-on détecter les protéines CRISPR par imagerie ?\nQuels marqueurs sont spécifiques aux protéines CRISPR ?\nComment évaluer l'activité des protéines CRISPR ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Data+Accuracy#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines associées aux CRISPR",
"description": "Quels symptômes sont liés à des dysfonctionnements CRISPR ?\nLes protéines CRISPR causent-elles des effets secondaires ?\nComment les protéines CRISPR affectent-elles la santé ?\nY a-t-il des symptômes d'allergie aux protéines CRISPR ?\nLes protéines CRISPR peuvent-elles provoquer des cancers ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Data+Accuracy#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines associées aux CRISPR",
"description": "Comment prévenir les maladies liées aux protéines CRISPR ?\nLes vaccins peuvent-ils intégrer CRISPR ?\nY a-t-il des mesures préventives pour les traitements CRISPR ?\nComment éduquer sur les risques des CRISPR ?\nLes tests génétiques peuvent-ils prévenir des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Data+Accuracy#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines associées aux CRISPR",
"description": "Comment les protéines CRISPR sont-elles utilisées en thérapie ?\nQuels types de maladies peuvent être traités avec CRISPR ?\nY a-t-il des traitements en cours avec CRISPR ?\nQuels sont les défis des traitements CRISPR ?\nCRISPR peut-il être utilisé pour des maladies infectieuses ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Data+Accuracy#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines associées aux CRISPR",
"description": "Quelles complications peuvent survenir avec CRISPR ?\nComment gérer les complications des traitements CRISPR ?\nLes complications sont-elles fréquentes avec CRISPR ?\nQuelles sont les conséquences des effets hors cible ?\nLes complications peuvent-elles être réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Data+Accuracy#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines associées aux CRISPR",
"description": "Quels sont les facteurs de risque pour les traitements CRISPR ?\nLes mutations génétiques augmentent-elles les risques ?\nL'environnement influence-t-il les risques liés à CRISPR ?\nLes antécédents familiaux sont-ils un facteur de risque ?\nLes traitements antérieurs affectent-ils les risques ?",
"url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Data+Accuracy#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les protéines CRISPR dans un échantillon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques comme la PCR et le séquençage."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les protéines associées ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'immunobuvardage et de chromatographie peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les protéines CRISPR par imagerie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques comme la microscopie à fluorescence peuvent être utilisées."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont spécifiques aux protéines CRISPR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs spécifiques incluent les séquences génétiques uniques des gènes cas."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des protéines CRISPR ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activité peut être évaluée par des tests de coupure d'ADN et d'édition génétique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des dysfonctionnements CRISPR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure des anomalies génétiques et des maladies héréditaires."
}
},
{
"@type": "Question",
"name": "Les protéines CRISPR causent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent survenir, comme des réponses immunitaires indésirables."
}
},
{
"@type": "Question",
"name": "Comment les protéines CRISPR affectent-elles la santé ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent influencer la santé en modifiant des gènes liés à des maladies."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes d'allergie aux protéines CRISPR ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques peuvent survenir, mais elles sont rares et peu documentées."
}
},
{
"@type": "Question",
"name": "Les protéines CRISPR peuvent-elles provoquer des cancers ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications génétiques inappropriées peuvent augmenter le risque de cancer."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées aux protéines CRISPR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des dépistages génétiques et des conseils en génétique."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils intégrer CRISPR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent l'utilisation de CRISPR pour améliorer les vaccins existants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les traitements CRISPR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures incluent le suivi des effets secondaires et l'évaluation des risques."
}
},
{
"@type": "Question",
"name": "Comment éduquer sur les risques des CRISPR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation passe par des campagnes d'information et des ressources en santé publique."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques permettent d'identifier les risques et de prendre des mesures."
}
},
{
"@type": "Question",
"name": "Comment les protéines CRISPR sont-elles utilisées en thérapie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour corriger des mutations génétiques dans des thérapies géniques."
}
},
{
"@type": "Question",
"name": "Quels types de maladies peuvent être traités avec CRISPR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "CRISPR peut traiter des maladies génétiques, des cancers et des infections virales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements en cours avec CRISPR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques explorent l'utilisation de CRISPR pour diverses maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les défis des traitements CRISPR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les défis incluent la précision de l'édition et les effets hors cible potentiels."
}
},
{
"@type": "Question",
"name": "CRISPR peut-il être utilisé pour des maladies infectieuses ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CRISPR est exploré pour cibler et éliminer des virus dans des infections."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CRISPR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des modifications hors cible et des réactions immunitaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des traitements CRISPR ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical rigoureux et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec CRISPR ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences des effets hors cible ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets hors cible peuvent entraîner des mutations indésirables et des maladies."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles, mais cela dépend du cas spécifique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les traitements CRISPR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'état de santé et les antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques augmentent-elles les risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations peuvent accroître le risque de complications avec CRISPR."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il les risques liés à CRISPR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'environnement peut jouer un rôle dans l'expression des gènes modifiés."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs affectent-ils les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements antérieurs peuvent influencer la réponse aux thérapies CRISPR."
}
}
]
}
]
}
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Publications dans "Protéines associées aux CRISPR" :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Electronic address: fengyue@mail.buct.edu.cn.
Publications dans "Protéines associées aux CRISPR" :
Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94143, USA.
Publications dans "Protéines associées aux CRISPR" :
Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: alan.davidson@utoronto.ca.
Publications dans "Protéines associées aux CRISPR" :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Jiangxi Provincial Key Laboratory of Natural Active Pharmaceutical Constituents, Department of Chemistry and Bioengineering, Yichun University, Yichun, China.
Publications dans "Protéines associées aux CRISPR" :
Institute of Pharmacy and Molecular Biotechnology (IPMB), Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany. dominik.niopek@uni-heidelberg.de.
Publications dans "Protéines associées aux CRISPR" :
College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea; Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, 06974, Republic of Korea. Electronic address: xrayleox@cau.ac.kr.
Publications dans "Protéines associées aux CRISPR" :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Jiangxi Provincial Key Laboratory of Natural Active Pharmaceutical Constituents, Department of Chemistry and Bioengineering, Yichun University, Yichun, China.
Publications dans "Protéines associées aux CRISPR" :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China; Key Laboratory of Livestock Infectious Diseases in Northeast China, Ministry of Education, College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, Liaoning Province, Shenyang 110866, China. Electronic address: zeliangchen@yahoo.com.
Publications dans "Protéines associées aux CRISPR" :
RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA; email: Jooyoung.Lee@umassmed.edu, Erik.Sontheimer@umassmed.edu.
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Publications dans "Protéines associées aux CRISPR" :
In the medical field, we face many challenges, including the high cost of data collection and processing, difficult standards issues, and complex preprocessing techniques. It is necessary to establish...
We defined the data quality management system from three aspects (Construction - Operation - Utilization) based on the life cycle of medical data. Based on this, we proposed the "SMART DATA" concept a...
We define "SMART DATA" as systematized, high-quality data collected based on the life cycle of data construction, operation, and utilization through quality control activities for medical data. In thi...
In this study, we conducted primary research to develop a medical data quality management system. This will standardize medical data extraction and quality control methods and increase the utilization...
To assess the prevalence of overly positive interpretation, also called 'spin',-of results in diagnostic accuracy studies of infectious diseases and to identify suggestions for improvement....
A PubMed search was performed to identify diagnostic accuracy studies of infectious diseases published between January and March 2019. Each article was assessed by two authors independently to identif...
The final analysis included 120 studies. Favourable or promising recommendations were made in the main text of 101 (84%) of the included studies. Evidence of actual over-interpretation (spin) was foun...
Evidence of over-interpretation of results was found in one-third of the included studies. We have proposed possible interventions to prevent overly positive interpretations of results in diagnostic a...
We describe the design, implementation, and impact of a data harmonization, data quality checking, and dynamic report generation application in an international observational HIV research network. The...
For a long time, the reliability of medical-scientific research was, without further verification, based on real data. It is becoming increasingly clear that this assumption is unjustified and that pr...
Although ChatGPT was not developed for medical use, there is growing interest in its use in medical fields. Understanding its capabilities and precautions for its use in the medical field is an urgent...
A non-clinical experimental study....
We administered the Japanese National Medical Examination to GPT-3.5 and GPT-4 to examine the rates of accuracy and consistency in their responses. We counted the total number of documents in the Web ...
For GPT-4, we confirmed an accuracy rate of 81.0 % and a consistency rate of 88.8 % on the exam; both showed improvement compared to those for GPT-3.5. A positive correlation was observed between the ...
Checking consistency may help identify incorrect answers when using ChatGPT. Users should be aware that the accuracy of the answers by ChatGPT may decrease when it is asked about topics with limited p...
Pairing of the T cell receptor (TCR) with its cognate peptide-MHC (pMHC) is a cornerstone in T cell-mediated immunity. Recently, single-cell sequencing coupled with DNA-barcoded MHC multimer staining ...
Digital transformation in healthcare and the growth of health data generation and collection are important challenges for the secondary use of healthcare records in the health research field. Likewise...
To capture the different data governance behind health data hubs across Europe, a survey focused on analysing the feasibility of linking individual-level data between data collections and the generati...
In total, 41 survey responses received until June 2022 were analysed. Stratification methods were performed to cover the different levels of granularity identified in some data hubs' characteristics. ...
The analysis of the responses from health data hub respondents across Europe provided a list of the most frequent aspects, which concluded with a set of specific best practices on data management and ...
Unstructured text data (UTD) are increasingly found in many databases that were never intended to be used for research, including electronic medical record (EMR) databases. Data quality can impact the...
Our objective was to systematically document current research and practices about NLP preprocessing methods to describe or improve the quality of UTD, including UTD found in EMR databases....
A scoping review was undertaken of peer-reviewed studies published between December 2002 and January 2021. Scopus, Web of Science, ProQuest, and EBSCOhost were searched for literature relevant to the ...
A total of 41 articles were included in the scoping review; over 50% were published between 2016 and 2021. Almost 20% of the articles were published in health science journals. Common preprocessing me...
Multiple NLP techniques have been proposed to preprocess UTD, with some differences in techniques applied to EMR data. There are similarities in the data quality dimensions used to characterize struct...
In this evaluation, we aim to strengthen Routine Health Information Systems (RHIS) through the digitization of data quality assessment (DQA) processes. We leverage electronic data from the Kenya Healt...
We evaluated 187 HIV care facilities with electronic medical records across Kenya. Using quarterly, longitudinal KHIS data from January 2011 to June 2018 (total N = 30 quarters), we extracted indicato...
A total of 5,610 unique facility-quarters were extracted from KHIS. The mean completeness score was 61.1% [standard deviation (SD) = 27%]. The mean consistency score was 80% (SD = 16.4%). The mean dis...
We observed a lack of correlation between the completeness score and the other two scores. As such, for a holistic DQA, completeness assessment should be paired with the measurement of either consiste...
Groundwater overuse in different domains will eventually lead to global freshwater scarcity. To meet the anticipated demands, many governments worldwide are employing innovative and traditional techni...
